X0202 SCHEDULE 13D/A 0001072613-19-000288 0001666306 XXXXXXXX LIVE 8 Common Stock, $0.0001 par value 11/04/2026 false 0001706431 92764N102 Vir Biotechnology, Inc.

1800 Owens Street, Suite 900 San Francisco CA 94158

Mark McDonnell (773) 380-6600 ARCH Venture Management, LLC 8755 W. Higgins Road, Suite 1025 Chicago IL 60631 0001666306 N ARCH Venture Fund IX, L.P. WC N DE 0 11897988 0 11897988 11897988 N 6.9 PN 0001666307 N ARCH Venture Fund IX Overage, L.P. WC N DE 0 11897988 0 11897988 11897988 N 6.9 PN 0001723173 N ARCH Venture Partners IX, L.P. AF N DE 0 11897988 0 11897988 11897988 N 6.9 PN 0001723172 N ARCH Venture Partners IX Overage, L.P. WC N DE 0 11897988 0 11897988 11897988 N 6.9 PN 0001723174 N ARCH Venture Partners IX, LLC AF N DE 0 11897988 0 11897988 11897988 N 6.9 OO 0001219042 N Robert Nelsen AF N X1 576148 11931881 576148 11931881 12508029 N 7.3 IN 0001219039 N Keith Crandell AF N X1 272964 11897988 272964 11897988 12170952 N 7.1 IN 0001219043 N Clinton Bybee AF N X1 30570 11959148 30570 11959148 11989718 N 7.0 IN Common Stock, $0.0001 par value Vir Biotechnology, Inc. 1800 Owens Street, Suite 900 San Francisco CA 94158 This Amendment No. 8 (the "Amendment No.8") amends the statement on Schedule 13D filed on November 8, 2019 (as amended, the "Original 13D"), relating to the Common Stock, $0.0001 par value per share (the "Common Stock"), of Vir Biotechnology, Inc. (the "Issuer") having its principal executive office at 1800 Owens Street, Suite 900, San Francisco, California 94158. Certain terms used but not defined in this Amendment No. 8 have the meanings assigned thereto in the Original 13D. Each of AVF IX and AVF IX Overage acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF IX and AVF IX Overage and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. From November 3, 2026 to November 5, 2026, AVF IX and AVF IX Overage sold 347,819 shares and 448,356 shares respectively, of Common Stock for cash. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above. Items 5(a)-(c) of the Original 13D are hereby amended and supplemented as follows: AVF IX is the record owner of 5,055,689 shares of Common Stock ("AVF IX Record Shares"). AVP IX LP, as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Record Shares. AVP IX LLC, as the sole general partner of AVP IX LP, may be deemed to beneficially own the AVF IX Record Shares. AVF IX Overage is the record holder of 6,842,299 shares of Common Stock ("IX Overage Record Shares" and, together with the AVF IX Record Shares, the "Record Shares"). AVP IX Overage GP, as the sole general partner of AVF IX Overage, may be deemed to beneficially own the IX Overage Record Shares. AVP IX LLC, as the sole general partner of AVP IX Overage GP, may be deemed to beneficially own the IX Overage Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each entity and Reporting Person may be deemed to share the power to direct the disposition and vote of the Record Shares. In addition, each of the AVP IX Managing Directors may be deemed to share the power to direct the disposition and vote of the Record Shares. Each Reporting Person disclaims beneficial ownership of all securities except for the shares, if any, held of record by such Reporting Person. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on the 171,270,773 shares of Common Stock outstanding as of October 28, 2026 as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 4, 2026. In addition, as of November 6, 2026, Crandell is a record holder of 272,964 Shares of Common Stock, Bybee is a record holder of 30,570 shares of Common Stock, and Nelsen separately holds 576,148 shares of Common Stock. For Nelsen and Bybee, respectively, 33,893 shares and 61,160 shares of Common Stock held by family trusts are included in Shared Voting and Shared Dispositive figures on cover sheets. Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets. Except as set forth in the following, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days: On November 3, 2026, AVF IX sold 94,905 shares of Common Stock and AVF IX Overage sold 122,337 shares of Common Stock at a weighted average sale price of $11.24 per share, in multiple transactions at prices ranging from $11.10 to $11.37, inclusive. On November 4, 2026, AVF IX sold 146,562 shares of Common Stock and AVF IX Overage sold 188,926 shares of Common Stock at a weighted average sale price of $11.60 per share, in multiple transactions at prices ranging from $11.17 to $11.81, inclusive. On November 5, 2026, AVF IX sold 99,274 shares of Common Stock and AVF IX Overage sold 127,970 shares of Common Stock at a weighted average sale price of $11.26 per share, in multiple transactions at prices ranging from $10.98 to $11.98, inclusive. On November 5, 2026, AVF IX sold 7,078 shares of Common Stock and AVF IX Overage sold 9,123 shares of Common Stock at a weighted average sale price of $12.06 per share, in multiple transactions at prices ranging from $11.99 to $12.16, inclusive. The reported prices are weighted average prices. The Reporting Persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range. ARCH Venture Fund IX, L.P. ARCH Venture Partners IX, L.P. 11/06/2026 ARCH Venture Partners IX, LLC 11/06/2026 /s/ Mark McDonnell 11/06/2026 ARCH Venture Fund IX Overage, L.P. ARCH Venture Partners IX Overage, L.P. 11/06/2026 ARCH Venture Partners IX, LLC 11/06/2026 /s/ Mark McDonnell 11/06/2026 ARCH Venture Partners IX, L.P. ARCH Venture Partners IX, LLC 11/06/2026 /s/ Mark McDonnell 11/06/2026 ARCH Venture Partners IX Overage, L.P. ARCH Venture Partners IX, LLC 11/06/2026 /s/ Mark McDonnell 11/06/2026 ARCH Venture Partners IX, LLC /s/ Mark McDonnell 11/06/2026 Robert Nelsen /s/ Mark McDonnell 11/06/2026 Keith Crandell /s/ Mark McDonnell 11/06/2026 Clinton Bybee /s/ Mark McDonnell 11/06/2026 * This Amendment No. 8 to the Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Vir Biotechnology, Inc. by the Reporting Persons filed with the Securities and Exchange Commission on October 10, 2019 and incorporated herein in its entirety by reference.